查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1263963

液態切片的全球市場:市場規模，趨勢，成長分析(2022年～2027年)

Liquid Biopsy Market: Market Size, Trends and Growth Analysis [2022-2027]
出版日期: | 出版商: Lucintel | 英文 264 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球液態切片的市場規模，預計至2027年達到86億美元，2022年～2027年以14.5％的年複合成長率成長。市場主要促進因素，是癌症的流行，及對非侵入性治療的偏好，對高精度的疾病的即時早期發現的需求增加。

本報告提供全球液態切片市場相關調查分析，趨勢與預測，成長機會分析，企業簡介等資訊。

目錄

第1章 摘要整理

第2章 全球液態切片市場背景與分類

  • 簡介，背景及分類
  • 供應鏈
  • 產業的推動因素與課題

第3章 市場趨勢與預測分析(2015年～2026年)

  • 宏觀經濟的趨勢與預測
  • 全球液態切片市場趨勢與預測
  • 全球液態切片市場:各產品
    • 化驗套件
    • 器具
    • 服務
  • 全球液態切片市場:各循環生物標記
    • 循環腫瘤細胞(CTC)
    • 循環腫瘤DNA(ctDNA)
    • 無細胞DNA(cfDNA)
    • 細胞外小胞(EV)
    • 其他的循環生物標記
  • 全球液態切片市場:各用途
    • 癌症
      • 肺癌症
      • 乳癌
      • 大腸癌症
      • 前列腺癌症
      • 肝臟癌症
      • 其他的癌症
    • 非癌症
  • 全球液態切片市場:各臨床應用
    • 早期癌症的篩檢
    • 治療方法的選擇
    • 治療監測
    • 復發監測
  • 全球液態切片市場:各終端用戶
    • 參考文件實驗室
    • 醫院，醫生的研究所
    • 學術，研究中心
    • 其他的終端用戶

第4章 市場趨勢與預測分析(2015年～2026年)

  • 全球液態切片市場:各地區
  • 北美的液態切片市場趨勢與預測
    • 北美的液態切片市場:各產品
    • 北美的液態切片市場:各循環生物標記
    • 北美的液態切片市場:各用途
    • 北美的液態切片市場:各臨床應用
    • 北美的液態切片市場:各最終用途
    • 美國的液態切片市場
    • 加拿大的液態切片市場
    • 墨西哥的液態切片市場
  • 歐洲的液態切片市場趨勢與預測
    • 歐洲的液態切片市場:各產品
    • 歐洲的液態切片市場:各循環生物標記
    • 歐洲的液態切片市場:各用途
    • 歐洲的液態切片市場:各臨床應用
    • 歐洲的液態切片市場:各最終用途
    • 英國的液態切片市場
    • 德國的液態切片市場
    • 法國的液態切片市場
    • 義大利的液態切片市場
    • 西班牙的液態切片市場
  • 亞太地區的液態切片市場趨勢與預測
    • 亞太地區的液態切片市場:各產品
    • 亞太地區的液態切片市場:各循環生物標記
    • 亞太地區的液態切片市場:各用途
    • 亞太地區的液態切片市場:各臨床應用
    • 亞太地區的液態切片市場:各最終用途
    • 日本的液態切片市場
    • 中國的液態切片市場
    • 印度的液態切片市場
  • 其他地區的液態切片市場趨勢與預測
    • 其他地區的液態切片市場:各產品
    • 其他地區的液態切片市場:各循環生物標記
    • 其他地區的液態切片市場:各用途
    • 其他地區的液態切片市場:各臨床應用
    • 其他地區的液態切片市場:各最終用途
    • 巴西的液態切片市場

第5章 競爭的分析

  • 產品系列分析
  • 市場佔有率分析
  • 經營的整合
  • 地理有效半徑
  • 波特的五力分析

第6章 成長機會及策略的分析

  • 成長機會分析
    • 全球液態切片市場成長機會:各產品
    • 全球液態切片市場成長機會:各循環生物標記
    • 全球液態切片市場成長機會:各用途
    • 全球液態切片市場成長機會:各臨床應用
    • 全球液態切片市場成長機會:各最終用途
    • 全球液態切片市場成長機會:各地區
  • 全球液態切片市場上新的趨勢
  • 策略的分析
    • 新產品的開發
    • 授權與認證
    • 全球液態切片市場的合併，收購，合資企業，其他的聯盟

第7章 主要企業的企業簡介

  • Bio-Rad Laboratories
  • QIAGEN
  • MDxHealth
  • Myriad Genetics
  • Biocept, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Cardiff Oncology
  • Guardant Health
簡介目錄

Liquid Biopsy Market Trends and Forecast

The future of the global liquid biopsy market looks promising with opportunities in reference laboratories, hospitals and physician laboratories, and academic and research centers. The global liquid biopsy market is expected to reach an estimated $8.6 billion by 2027 with a CAGR of 14.5% from 2022 to 2027. The major drivers for this market are the increasing prevalence of cancer, preference for non-invasive procedures, and increasing need of early detection of high precision diseases in real time.

Emerging Trends in Liquid Biopsy Market

Emerging trends, which have a direct impact on the dynamics of the industry, include the usage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector.

A total of 163 figures / charts and 129 tables are provided in this 264-page report to help in your business decisions. Sample figures with some insights are shown below.

Liquid Biopsy Market by Segment

In this market, therapy selection is the largest clinical application market, and circulating tumor DNA is the largest circulating biomarker segment. Growth in various segments of the liquid biopsy market are shown in the figure below.

The study includes trends and forecast for the global liquid biopsy market by product, circulating biomarker, application, clinical application, end use, and region as follows:

Liquid Biopsy Market by Product [Value ($M) from 2016 to 2027]:

  • Assays Kits
  • Instruments
  • Services

Liquid Biopsy Market by Circulating Biomarker [Value ($M) from 2016 to 2027]:

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (CtDNA)
  • Cell-Free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Other Biomarkers

Liquid Biopsy Market by Application [Value ($M) from 2016 to 2027]:

  • Oncology

Lung Cancer

Breast Cancer

Colorectal Cancer

Prostate Cancer

Liver Cancer

Other Cancers

  • Non-Cancer

Liquid Biopsy Market by Clinical Application [Value ($M) from 2016 to 2027]:

  • Early Cancer Screening
  • Therapy Selection
  • Treatment Monitoring
  • Recurrence Monitoring

Liquid Biopsy Market by End Use [Value ($M) from 2016 to 2027]:

  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Academic and Research Centers
  • Other End Uses

Liquid Biopsy Market by Region [Value ($M) from 2016 to 2027]:

  • North America

US

Canada

Mexico

  • Europe

United Kingdom

France

Germany

Italy

Spain

  • APAC

China

Japan

India

  • ROW

Brazil

List of Liquid Biopsy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, liquid biopsy companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the liquid biopsy companies profiled in this report include-

  • Guardant
  • Bio-Rad Laboratories
  • Qiagen
  • MDxHealth
  • Myriad Genetics
  • Biocept
  • Roche
  • Illumina
  • Thermofisher

Liquid Biopsy Market Insights

  • Lucintel forecasts circulating tumor DNA will remain the largest segment and is also expected to witness the highest growth over the forecast period due to increasing use of ctDNA biomarkers in next-generation sequencing (NGS) technologies for detecting diseases in real time and in early stage.
  • Therapy selection will remain the largest clinical application over the forecast period due to its offerings of various benefits, such as non-invasiveness, access to tumor heterogeneity, real-time treatment monitoring, and recurrence detection in advance of significant tumor formation or metastasis.
  • APAC will remain the fastest growing region over the forecast period due to rising non-invasive treatment, a rising incidence of cancer, and improving healthcare infrastructure.

Features of the Global Liquid Biopsy Market

  • Market Size Estimates: Global liquid biopsy market size estimation in terms of value ($B) shipment.
  • Trend and Forecast Analysis: Market trends (2016-2021) and forecast (2022-2027) by various segments.
  • Segmentation Analysis:Global liquid biopsy market size by product, circulating biomarker, application, clinical application, end use, and region in terms of value.
  • Regional Analysis: Global liquid biopsy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different by product, circulating biomarker, application, clinical application, end use, and region for the global liquid biopsy market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global liquid biopsy market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model

FAQ

Q1. What is theliquid biopsy marketsize?

Answer:The global liquid biopsy market is expected to reach an estimated $10.4 billion by 2026.

Q2. What is the growth forecast for theliquid biopsy market?

Answer:The global liquid biopsy market is expected to grow at a CAGR of ~17% from 2020 to 2026.

Q3. What are the major drivers influencing the growth of theliquid biopsy market?

Answer: The major drivers for this market are increasing prevalence of cancer, preference for non-invasive procedures, and increasing need for early detection of high precision diseases in real time.

Q4. What are the major clinical applications of theliquid biopsy market?

Answer:Early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring are the major clinical application segments of liquid biopsy.

Q5. What are the emerging trends in theliquid biopsy market?

Answer:Emerging trends, which have a direct impact on the dynamics of the industry, include the usage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector.

Q6. Who are the keyliquid biopsy companies?

Answer:Some of the key liquid biopsy companies are as follows:

  • Guardant
  • Bio-Rad Laboratories
  • Qiagen
  • MDxHealth
  • Myriid Genetics
  • Biocept
  • Roche
  • Illumina
  • Thermofisher

Q7.Which will be the largestcirculating biomarker segment of theliquid biopsy marketin the future?

Answer: Lucintel forecasts that circulating tumor DNA (ctDNA) will remain the largest segment, and it is also expected to witness the highest growth over the forecast period due to increasing use of ctDNA biomarkers in next-generation sequencing (NGS) technologies for detecting diseases in real time and in the early stage.

Q8: Inliquid biopsy market, which region is expected to be the largest in the next five years?

Answer:Asia Pacific is expected to be the largest region over the next five years.

Q9. Do we receive customization in this report?

Answer:Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions

  • Q.1 What are some of the most promising growth opportunities for the global liquid biopsy market by product (assay kits, instruments, and services), circulating biomarker (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers), application (oncology and non-cancer liquid biopsies), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring), end use (reference laboratories, hospitals and physician laboratories, academic and research centers, and other end uses), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2 Which segments will grow at a faster pace and why?
  • Q.3 Which region will grow at a faster pace and why?
  • Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global liquid biopsy market?
  • Q.5 What are the business risks and threats to the global liquid biopsy market?
  • Q.6 What are the emerging trends in this liquid biopsy market and the reasons behind them?
  • Q.7 What are some changing demands of customers in the liquid biopsy market?
  • Q.8 What are the new developments in the liquid biopsy market? Which companies are leading these developments?
  • Q.9 Who are the major players in the liquid biopsy market? What strategic initiatives are being implemented by key players for business growth?
  • Q.10 What are some of the competitive products and processes in the liquid biopsy market, and how big of a threat do they pose for loss of market share via material or product substitution?
  • Q.11 What M&A activities did take place in the last five years in the global liquid biopsy market?

Table of Contents

1. Executive Summary

2. Global Liquid Biopsy Market Background and Classifications

  • 2.1: Introduction, Background and Classification
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2015 to 2026

  • 3.1: Macroeconomic Trends and Forecasts
  • 3.2: Global Liquid Biopsy Market Trends and Forecast
  • 3.3: Global Liquid Biopsy Market by Product
    • 3.3.1: Assay Kits
    • 3.3.2: Instruments
    • 3.3.3: Services
  • 3.4: Global Liquid Biopsy Market by Circulating Biomarker
    • 3.4.1: Circulating Tumor Cells (CTCs)
    • 3.4.2: Circulating Tumor DNA (ctDNA)
    • 3.4.3: Cell-Free DNA (cfDNA)
    • 3.4.4: Extracellular Vesicles (EVs)
    • 3.4.5: Other Circulating Biomarkers
  • 3.5: Global Liquid Biopsy Market by Application
    • 3.5.1: Oncology
      • 3.5.1.1: Lung Cancer
      • 3.5.1.2: Breast Cancer
      • 3.5.1.3: Colorectal Cancer
      • 3.5.1.4: Prostate Cancer
      • 3.5.1.5: Liver Cancer
      • 3.5.1.6: Other Cancer
    • 3.5.2: Non-Cancer
  • 3.6: Global Liquid Biopsy Market by Clinical Application
    • 3.6.1: Early Cancer Screening
    • 3.6.2: Therapy Selection
    • 3.6.3: Treatment Monitoring
    • 3.6.4: Recurrence Monitoring
  • 3.7: Global Liquid Biopsy Market by End User
    • 3.7.1: Reference Laboratories
    • 3.7.2: Hospitals and Physician Laboratories
    • 3.7.3: Academic and Research Centers
    • 3.7.4: Other End Users

4. Market Trends and Forecast Analysis from 2015 to 2026

  • 4.1: Global Liquid Biopsy Market by Region
  • 4.2: North American Liquid Biopsy Market Trends and Forecast
    • 4.2.1: North American Liquid Biopsy Market by Product
    • 4.2.2: North American Liquid Biopsy Market by Circulating Biomarker
    • 4.2.3: North American Liquid Biopsy Market by Application
    • 4.2.4: North American Liquid Biopsy Market by Clinical Application
    • 4.2.5: North American Liquid Biopsy Market by End Use
    • 4.2.6: United States Liquid Biopsy Market
    • 4.2.7: Canadian Liquid Biopsy Market
    • 4.2.8: Mexican Liquid Biopsy Market
  • 4.3: European Liquid Biopsy Market Trends and Forecast
    • 4.3.1: European Liquid Biopsy Market by Product
    • 4.3.2: European Liquid Biopsy Market by Circulating Biomarker
    • 4.3.3: European Liquid Biopsy Market by Application
    • 4.3.4: European Liquid Biopsy Market by Clinical Application
    • 4.3.5: European Liquid Biopsy Market by End Use
    • 4.3.6: United Kingdom Liquid Biopsy Market
    • 4.3.7: German Liquid Biopsy Market
    • 4.3.8: French Liquid Biopsy Market
    • 4.3.9: Italian Liquid Biopsy Market
    • 4.3.10: Spanish Liquid Biopsy Market
  • 4.4: APAC Liquid Biopsy Market Trends and Forecast
    • 4.4.1: APAC Liquid Biopsy Market by Product
    • 4.4.2: APAC Liquid Biopsy Market by Circulating Biomarker
    • 4.4.3: APAC Liquid Biopsy Market by Application
    • 4.4.4: APAC Liquid Biopsy Market by Clinical Application
    • 4.4.5: APAC Liquid Biopsy Market by End Use
    • 4.4.6: Japanese Liquid Biopsy Market
    • 4.4.7: Chinese Liquid Biopsy Market
    • 4.4.8: Indian Liquid Biopsy Market
  • 4.5: ROW Liquid Biopsy Market Trends and Forecast
    • 4.5.1: ROW Liquid Biopsy Market by Product
    • 4.5.2: ROW Liquid Biopsy Market by Circulating Biomarker
    • 4.5.3: ROW Liquid Biopsy Market by Application
    • 4.5.4: ROW Liquid Biopsy Market by Clinical Application
    • 4.5.5: ROW Liquid Biopsy Market by End Use
    • 4.5.6: Brazilian Liquid Biopsy Market

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Market Share Analysis
  • 5.3: Operational Integration
  • 5.4: Geographical Reach
  • 5.5: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Liquid Biopsy Market by Product
    • 6.1.2: Growth Opportunities for the Global Liquid Biopsy Market by Circulating Biomarker
    • 6.1.3: Growth Opportunities for the Global Liquid Biopsy Market by Application
    • 6.1.4: Growth Opportunities for the Global Liquid Biopsy Market by Clinical Application
    • 6.1.5: Growth Opportunities for the Global Liquid Biopsy Market by End Use
    • 6.1.6: Growth Opportunities for the Global Liquid Biopsy Market by Region
  • 6.2: Emerging Trends in the Global Liquid Biopsy Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Licensing and Certification
    • 6.3.3: Mergers, Acquisitions, Joint Ventures, and Other Collaborations in the Global Liquid Biopsy Market

7. Company Profiles of Leading Players

  • 7.1: Bio-Rad Laboratories
  • 7.2: QIAGEN
  • 7.3: MDxHealth
  • 7.4: Myriad Genetics
  • 7.5: Biocept, Inc.
  • 7.6: F. Hoffmann-La Roche Ltd.
  • 7.7: Thermo Fisher Scientific Inc.
  • 7.8: Illumina, Inc.
  • 7.9: Cardiff Oncology
  • 7.10: Guardant Health